A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1627-1638

  Mehrotra, Shikhar ^a   Al Khami, Amir A ^a   Klarquist, Jared ^b   Husain, Shahid ^a   Naga, Osama ^a   Eby, Jonathan M ^b   Murali, Anuradha K ^a   Lyons, Gretchen E ^c   Li, Mingli ^a   Spivey, Natali D ^a   Norell, Håkan ^a   Da Palma, Telma Martins ^a   Onicescu, Georgiana ^a   Diaz Montero, C Marcela ^a   Garrett Mayer, Elizabeth ^a   Cole, David J ^a   Le Poole, I Caroline ^b   Nishimura, Michael I ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN CORECEPTOR; CD8 ANTIGEN; CD8 ANTIGEN CORECEPTOR; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER CONTROL; CANCER INHIBITION; CD3+ CD4- CD8- T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD4- CD8- T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEPIGMENTATION; HAIR COLOR; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VISUAL DISORDER;

ANIMALS; ANTIGENS, CD3; AUTOIMMUNITY; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS;

EID: 84864800623     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103271     Document Type: Article

References (44)

1. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308. (Pubitemid 351430867)
2. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513. (Pubitemid 29295880)
3. Duval, L., H. Schmidt, K. Kaltoft, K. Fode, J. J. Jensen, S. M. Sorensen, M. I. Nishimura, and H. von der Maase. 2006. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin. Cancer Res. 12: 1229-1236. (Pubitemid 43342513)
4. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
5. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915. (Pubitemid 39273730)
6. Becerra, J. C., J. F. Arthur, G. R. Landucci, D. N. Forthal, and C. P. Theuer. 2003. CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery 133: 404-410. (Pubitemid 36515329)
7. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580. (Pubitemid 37040391)
8. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
9. Li, L. P., J. C. Lampert, X. Chen, C. Leitao, J. Popović, W. Müller, and T. Blankenstein. 2010. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16: 1029-1034.
10. von Boehmer, H. 1990. Developmental biology of T cells in T cell-receptor transgenic mice. Annu. Rev. Immunol. 8: 531-556.
11. Kouskoff, V., K. Signorelli, C. Benoist, and D. Mathis. 1995. Cassette vectors directing expression of T cell receptor genes in transgenic mice. J. Immunol. Methods 180: 273-280.
12. Rivoltini, L., K. C. Barracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, et al. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55: 3149-3157.
13. Mehrotra, S., R. Stevens, R. Zengou, N. G. Chakraborty, L. H. Butterfield, J. S. Economou, D. I. Dorsky, and B. Mukherji. 2003. Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res. 63: 5607-5614. (Pubitemid 37139885)
14. Bagasra, O. 2007. Protocols for the in situ PCR-amplification and detection of mRNA and DNA sequences. Nat. Protoc. 2: 2782-2795.
15. Le Poole, I. C., A. I. Riker, M. E. Quevedo, L. S. Stennett, E. Wang, F. M. Marincola, W. M. Kast, J. K. Robinson, and B. J. Nickoloff. 2002. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am. J. Pathol. 160: 521-528. (Pubitemid 34160329)
16. Halaban, R., and F. D. Alfano. 1984. Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 20: 447-450. (Pubitemid 15184812)
17. Husain, S., D. E. Potter, and C. E. Crosson. 2009. Opioid receptor-activation: retina protected from ischemic injury. Invest. Ophthalmol. Vis. Sci. 50: 3853-3859.
18. Yang, A. S., and P. Bird. 2009. Intracranial metastatic melanoma presenting with bilateral hearing loss. Otol. Neurotol. 30: 243-244.
19. Yeh, S., N. K. Karne, S. P. Kerkar, C. K. Heller, D. C. Palmer, L. A. Johnson, Z. Li, R. J. Bishop, W. T. Wong, R. M. Sherry, et al. 2009. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116: 981-989.e1.
20. Palmer, D. C., C. C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell, Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, et al. 2008. Effective tumor treatment targeting a melanoma/ melanocyteassociated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. USA 105: 8061-8066. (Pubitemid 351904708)
21. Currie, L., and A. Tomma. 2001. Malignant melanoma presenting as sudden onset of complete hearing loss. Ann. Plast. Surg. 47: 336-337. (Pubitemid 32847099)
22. von Boehmer, H., H. Kishi, P. Borgulya, B. Scott, W. van Ewijk, H. S. Teh, and P. Kisielow. 1989. Control of T-cell development by the TCR alpha beta for antigen. Cold Spring Harb. Symp. Quant. Biol. 54: 111-118. (Pubitemid 20177575)
23. von Boehmer, H. 1989. Learning by the immune system studied in T-cell receptor transgenic mice. Thymus 13: 19-26.
24. Nishimura, M. I., D. Avichezer, M. C. Custer, C. S. Lee, C. Chen, M. R. Parkhurst, R. A. Diamond, P. F. Robbins, D. J. Schwartzentruber, and S. A. Rosenberg. 1999. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res. 59: 6230-6238. (Pubitemid 30035647)
25. Huesmann, M., B. Scott, P. Kisielow, and H. von Boehmer. 1991. Kinetics and efficacy of positive selection in the thymus of normal and T cell receptor transgenic mice. Cell 66: 533-540. (Pubitemid 121001389)
26. Haas, J. P., M. Grunke, C. Frank, W. Kolowos, D. Dirnecker, G. Leipold, T. Hieronymus, H. M. Lorenz, and M. Herrmann. 1998. Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation. Cell Death Differ. 5: 751-757. (Pubitemid 28439115)
27. Merims, S., X. Li, B. Joe, P. Dokouhaki, M. Han, R. W. Childs, Z. Y. Wang, V. Gupta, M. D. Minden, and L. Zhang. 2011. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia 25: 1415-1422.
28. Voelkl, S., T. V. Moore, M. Rehli, M. I. Nishimura, A. Mackensen, and K. Fischer. 2009. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol. Immunother. 58: 709-718.
29. Zloza, A., M. C. Jagoda, G. E. Lyons, M. C. Graves, F. J. Kohlhapp, J. A. O'Sullivan, A. T. Lacek, M. I. Nishimura, and J. A. Guevara-Patiño. 2011. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunol. Immunother. 60: 291-297.
30. Thomson, C. W., B. P. Lee, and L. Zhang. 2006. Double-negative regulatory T cells: non-conventional regulators. Immunol. Res. 35: 163-178. (Pubitemid 44547511)
31. Lambe, T., J. C. Leung, T. Bouriez-Jones, K. Silver, K. Makinen, T. L. Crockford, H. Ferry, J. V. Forrester, and R. J. Cornall. 2006. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions. J. Immunol. 177: 3055-3062. (Pubitemid 44277822)
32. Gregg, R. K., L. Nichols, Y. Chen, B. Lu, and V. H. Engelhard. 2010. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinasespecific TCR transgenic mice. J. Immunol. 184: 1909-1917.
33. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191: 1221-1232.
34. Le Poole, I. C., R. M. van den Wijngaard, W. Westerhof, R. P. Dutrieux, and P. K. Das. 1993. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J. Invest. Dermatol. 100: 816-822. (Pubitemid 23151246)
35. Gargiulo, A., C. Bonetti, S. Montefusco, S. Neglia, U. Di Vicino, E. Marrocco, M. D. Corte, L. Domenici, A. Auricchio, and E. M. Surace. 2009. AAV-mediated tyrosinase gene transfer restores melanogenesis and retinal function in a model of oculo-cutaneous albinism type I (OCA1). Mol. Ther. 17: 1347-1354.
36. Raposo, G., and M. S. Marks. 2007. Melanosomes: dark organelles enlighten endosomal membrane transport. Nat. Rev. Mol. Cell Biol. 8: 786-797. (Pubitemid 47462136)
37. Greenberg, P. D., M. A. Cheever, and A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 154: 952-963. (Pubitemid 11060802)
38. Mumberg, D., P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96: 8633-8638. (Pubitemid 29354843)
39. Liu, Z., H. S. Noh, J. Chen, J. H. Kim, L. D. Falo, Jr., and Z. You. 2008. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J. Immunol. 181: 4363-4370.
40. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354. (Pubitemid 46890556)
41. Muranski, P., and N. P. Restifo. 2009. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr. Opin. Immunol. 21: 200-208.
42. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, et al. 2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
43. Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703. (Pubitemid 351860862)
44. Frankel, T. L., W. R. Burns, P. D. Peng, Z. Yu, D. Chinnasamy, J. A. Wargo, Z. Zheng, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2010. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 184: 5988-5998.